Objective
Gliomas describe a range of devastating and progressive brain tumours affecting around 25000 people each year in Europe. Glioblastomas represent the most severe and frequent form of gliomas. A major finding in the field of glioblastomas is the recent identification of cancer stem cells within the tumour, holding a high tumorigenic potential. Those stem cell-like cancer cells are multipotent and resistant to radio- and chemotherapy, and are thus very likely to be responsible for the tumour recurrence after surgical resection. They possess as well high migratory properties, strongly understudied so far. Their anarchic dispersion through the parenchyma of patients represents the main hurdle to surgical resection therapy, and their ability to re-generate a tumour threatens the therapeutic outcome. That is why a deep understanding of the mechanisms preferentially borrowed by glioma stem cells to spread and survive should lead to adapted therapeutic strategies. This project is based on the original discovery by JP Hugnot’s group that glioma cells can spontaneously express the neuroblast marker Dcx to enter a migratory program in vitro, and in vivo. Interestingly, Dcx+ and Dcx- glioma cells from the same culture share different migratory and tumorigenic properties. This project aims at deciphering the respective intrinsic properties of Dcx+ and Dcx- gliomas cells in terms of migration and tumorigenicity, and to identify which molecular pathways influence these properties (with a focus on Notch and Shh based on preliminary data). For that, several resources are already available and in Pr Hugnot’s group: cell sorting, gliomas cell lines reportering the expression of Dcx (Gli4 pDcx-GFP), migration assays, cell transplantation of Dcx+ or Dcx- cells in the brain of nude mice.
When further developed, these results will provide a substantial advance in the field of brain cancer research, and will open up significant therapeutic perspectives for the treatment of gliomas.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences clinical medicine oncology
- medical and health sciences clinical medicine transplantation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2011-IEF
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
75654 PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.